特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，山西省大气探测技术保障中心发布4项仪器设备采购意向，预算总额达1.89亿元，涉及无人机试验平台、双波长 四通道拉曼激光雷达、冰核采样与分析设备、二维成像降水粒子谱仪、微雨雷达、全天空成像仪、冰雹自动测量设备、 雹雨分测仪、GPS火箭气象探空系统、冰雹微物理结构分析实验室等，预计采购时间为2025年6~10月。 山西省大气探测技术保障中心 2025年6~10月 仪器设备采购 意向汇总表 | | | | 采 | | --- | --- | --- | --- | | | | 预算 | 购 | | 采购项目 | 需求概况 | 万元 | 时 | | | | | 间 | | | | | 202 | | | | | 5 | | 华北区域人工影响天气能力建设项目 | 国家作业飞机及机载大气探测子系统、机载催化作业子系统、空地通信子系统及空地综合业务系统联调 | 15634 | 年 | | （山西）-综合作业能力建设采购项目 | 测试。 | | 6 | | | | | 月 | | | | | 202 | ...

电子 证券研究报告 |公司深度研究 2025/06/11 聚光科技(300203)公司深度研究———— 行业龙头底蕴深厚，轻装上阵拐点已至 证券分析师: 张世杰(分析师) 证券分析师: 罗平(分析师) 分析师登记编号: S1190523020001 分析师登记编号: S1190524030001 报告摘要 P2 公司概况： 请务必阅读正文之后的免责条款部分 守正 出奇 宁静 致远 ➢ 国产高端仪器领军企业——轻装上阵，业绩转增。聚光科技（杭州）股份有限公司成立于2002年，总部位于中国杭 州，是一家以高端仪器装备产品技术为核心的高科技平台型企业。从产品布局上来看，公司始终坚持致力于高端分 析仪器的研制、产业化与创新应用，持续构建了"4+X"多对多业务布局，在智慧工业、智慧环境、智慧实验室与生 命科学四大板块的基础上培育孵化新的技术平台和应用公司，形成了创新的多个技术平台、多个客户群、多个应用 场景交叉支撑的业务模式。历史上公司营收及净利润波动较大。2023年开始，公司坚持以保障现金流为核心，持续 强化提高合同质量和营业收入质量。聚焦核心仪器业务，在停止签订PPP新合同的基础上，根据各个项目的具体情况， 差异化 ...

Core Viewpoint - The company, 聚光科技, has recently turned a profit after a series of losses, while its major shareholder, 浙江睿洋科技有限公司, has been continuously selling off its shares due to judicial rulings and financial needs [1][5]. Shareholder Changes - 浙江睿洋科技's shareholding in 聚光科技 has decreased from 16.45% to 12.85%, with a total of 57.65 million shares held [2][5]. - A significant portion of 浙江睿洋科技's shares, 46.35 million, has been frozen, representing 80.40% of its holdings and 10.33% of the total shares of 聚光科技 [5][8]. - The shareholder has been forced to sell shares through various judicial processes, including a recent auction of 2.3 million shares [4][5]. Financial Performance - 聚光科技 reported net losses of 232 million, 375 million, and 323 million yuan from 2021 to 2023, with a notable improvement in 2024, achieving a net profit of 207 million yuan [2][8]. - The company's revenue has been declining for three consecutive years, with figures of 3.751 billion, 3.451 billion, and 3.182 billion yuan from 2021 to 2023 [8]. - In the first quarter of 2025, 聚光科技 recorded a revenue of 547 million yuan, a year-on-year increase of 1.38%, but still reported a net loss of 20.52 million yuan [10]. Debt Situation - The company's debt ratio has been increasing, reaching 67.47% in 2023, but improved to 63.91% by the end of 2024 [8][10]. - As of the end of the first quarter of 2025, the debt ratio stood at 63.64% [3][10]. Strategic Adjustments - 聚光科技 has implemented measures to optimize its business structure, focusing on improving contract quality and cash flow management, while reducing non-profitable business lines [9]. - The company aims to strengthen its core business in high-end analytical instruments and is adjusting its product lines to focus on areas with significant growth opportunities [9].

Group 1 - The core point of the article is that Zhongke Instrument Co., Ltd. has completed the IPO counseling filing report with the Liaoning Securities Regulatory Bureau and plans to list on the Beijing Stock Exchange, with the counseling agency being China Merchants Securities [1] - Zhongke Instrument signed a counseling agreement on January 16, 2023, and conducted a total of 10 counseling sessions from January 17, 2023, to the date of the report [1] - During the counseling period, the listing board for Zhongke Instrument changed from the Sci-Tech Innovation Board to the Beijing Stock Exchange [1] - In 2020, Zhongke Instrument applied for an IPO on the Sci-Tech Innovation Board but withdrew the application in May 2021, leading to the termination of the review process by the Shanghai Stock Exchange [1] Group 2 - Zhongke Instrument was established in 2001 and specializes in the research, production, and sales of dry vacuum pumps and vacuum scientific instruments, as well as providing related technical services [1] - The company was recognized as a national-level specialized and innovative "little giant" enterprise by the Ministry of Industry and Information Technology in December 2020 [1] Group 3 - During the counseling process, it was discovered that retired employee Song Baian held shares on behalf of other retired employees and relatives, which has since been resolved with the shares sold and the proceeds returned to the rightful owners [3] - The company underwent a management restructuring during the counseling period, with Guo Dongmin becoming the chairman and Wang Guangyu becoming the general manager, while Kong Xiangling was newly appointed as the deputy general manager [5] - In January 2024, the company appointed Gong Jihua as the new financial director following a board meeting [5]

Core Points - The company has announced a cash dividend distribution of 0.35 RMB per share, totaling 35,035,000 RMB based on a total share capital of 100,100,000 shares [1][2][3] - The dividend distribution plan was approved at the annual shareholders' meeting held on May 29, 2025 [1] - The relevant dates for the dividend distribution include the record date, ex-dividend date, and payment date, which are specified in the announcement [1] Dividend Distribution Details - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [1][2] - For individual shareholders holding unrestricted circulating shares, the actual cash dividend of 0.35 RMB per share will be subject to personal income tax based on the holding period [3][4] - For qualified foreign institutional investors (QFII) and Hong Kong market investors, a withholding tax of 10% will apply, resulting in a net cash dividend of 0.315 RMB per share [4][5] Tax Implications - Individual shareholders holding shares for more than one year will be exempt from personal income tax on the dividend [3] - Shareholders holding shares for less than one year will have their dividends taxed based on their holding period, with specific rates outlined for different durations [3] - Other institutional investors and corporate shareholders will be responsible for their own tax declarations, with the gross cash dividend being 0.35 RMB per share [5]

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，仪器信息网汇总的2 0 2 4年全球科学仪器行业财报数据显示， 2 1家上市企业净利润总额达1 9 8亿元，同比微降， 行业平均净利润率从2 0 2 3年的1 5 . 7%下滑至11 . 6%。 这一数据背后，既折射出行业整体增速放缓的趋势，更揭示了企 业间战略分化加剧的新格局。 导读： 2024年全球科学仪器行业财报显示，21家上市企业净利润总额198亿元，同比下降，行业平均净利润率降至11.6%。头部企业 表现出色，而部分企业面临挑战。 | | | 2024年21家国外上市仪器企 | | | | | --- | --- | --- | --- | --- | --- | | | | 利润掉行榜 | | | | | 最新 | | | 2024年净利润 2023年净利润 | 净利润 | | | 扫名 | | 亿美元 | | 同比变化 | | | 1 | 手数 K | 63.4 | 59.6 | 6.4% | | | 2 | 丹纳赫 | 39.0 | 47.6 | -18.2% | | | ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近 年来，随着精准医疗与个体化治疗理念的持续推进，临床诊断对检测技术提出了更高要求，呈现出"更早期发现、更精准诊断、更全面评 估"的发展趋势。在这一背景下，质谱技术凭借其高灵敏度、高特异性以及多组分同时检测的能力，逐渐成为推动临床检验转型升级的重要技 术力量。 在临床应用中，质谱已广泛用于小分子物质的精准检测，同时逐步向蛋白质、肽类、核酸等大分子检测拓展，为疾病早期筛查、分型诊断和疗 效 评 估 提 供 了 更 加 可 靠 的 技 术 支 持 。 为 推 动 质 谱 技 术 在 临 床 诊 断 及 检 测 的 深 度 融 合 与 广 泛 应 用 ， 仪 器 信 息 网 网 络 讲 堂 于 2025 年 6 月 12 日 举 办"第四届临床质谱技术与应用进展网络研讨会"，共同展望临床质谱的未来发展路径。 会议时间： 2025年6月12日 主办单位： 仪器信息网 会议全日程： | | | | 0 | 09:30--10:00 | 便携式质谱指导胶质瘤手术的创新应用与展望 | 花玮 | 复旦大学附属 ...

导读： 本文深度聚焦国内50家上市仪器公司，通过解析2024年度研发投入金额、占比、人员规模等关键数据，绘制出一份全景式创新图谱。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 科学仪器，被誉为现代工业的"隐形基石"和科技创新的"眼睛与双手"。从基础研究到产业升级，从实验室探索到高端制造，仪器的精度与可靠 性直接决定着科研的高度与产业的质量。然而，这一关键领域曾长期被国际巨头垄断，国产仪器的"卡脖子"之痛，不仅关乎企业生存，更牵系 国家科技自主的战略安全。 近年来，政策东风频吹——从"十四五"规划的顶层设计，到财政专项的精准滴灌；从进口替代的硬性指标，到产学研协同的技术攻坚，国产科 学仪器行业正迎来前所未有的历史性机遇。在这场必须打赢的"逆袭战"中，研发投入成为企业竞争力的核心标尺：唯有真金白银砸向创新，才 能突破技术壁垒；唯有顶尖人才汇聚，方能锻造出与进口品牌抗衡的"中国精度"。 基于此，仪器信息网深度聚焦国内50家上市仪器企业，通过解析2024年度研发投入金额、占比、人员规模等关键数据，绘制出一份全景式创 新图谱。我们试图回答：谁在引 ...

Investment Rating - The report suggests a positive outlook for the scientific instruments industry, particularly in the context of domestic substitution driven by tariff uncertainties and export restrictions [4]. Core Insights - The scientific instruments market is undergoing a transformation, with domestic alternatives becoming essential due to increased import costs and supply chain risks [3][7]. - The analysis instruments market is experiencing growth, with the domestic market exceeding 30 billion yuan, and global market growth from 57.8 billion USD to 77.1 billion USD from 2017 to 2023, reflecting a CAGR of 4.92% [3][17]. - Increased R&D investment and supportive policies are expected to accelerate domestic substitution in the scientific instruments sector [3][27]. - The mass spectrometry and chromatography sectors face significant barriers, with high-end applications still dominated by foreign brands [3][4]. Summary by Sections Section 1: Domestic Substitution in Scientific Instruments - Tariff uncertainties and U.S. export controls are pushing for domestic alternatives in scientific instruments [7]. - The analysis instruments segment is a major branch of the scientific instruments industry, with high added value and a domestic market exceeding 30 billion yuan [17][11]. - R&D investment intensity is increasing, with 2024 funding reaching 3.61 trillion yuan, a growth of 8.3% year-on-year [25][26]. Section 2: Barriers in Mass Spectrometry and Chromatography - The mass spectrometry market in China reached 16.7 billion yuan in 2023, with a year-on-year growth of 19.53% [3][4]. - The chromatography market is projected to grow to around 16 billion yuan in 2024, with significant potential for domestic substitution [3][4]. Section 3: Innovation and Domestic Substitution - Companies like 聚光科技 (Juguang Technology) are turning losses into profits and expanding their business layout [4]. - 皖仪科技 (Wanyi Technology) is a leader in leak detection instruments, continuously investing in R&D [4]. - 莱伯泰科 (Leibotai Technology) is expanding from sample preparation to high-end analytical testing instruments [4]. - 雪迪龙 (Xuedilong) is actively positioning itself in the scientific instruments market, benefiting from the expansion of the carbon market [4].

Investment Rating - The report suggests a positive outlook for the scientific instruments industry, particularly in the context of domestic substitution driven by tariffs and export restrictions [4]. Core Insights - The scientific instruments market is undergoing a transformation due to increased tariffs and export controls from the U.S., pushing domestic alternatives from an option to a necessity [3][7]. - The analysis instruments market is experiencing continuous growth, with the domestic market exceeding 30 billion yuan, and the global market growing from 57.8 billion USD in 2017 to 77.1 billion USD in 2023, reflecting a CAGR of 4.92% [3][17]. - Increased R&D investment and supportive policies are expected to accelerate domestic substitution in the scientific instruments sector [3][27]. - The mass spectrometry and chromatography sectors face significant barriers, with high-end applications still dominated by foreign brands, indicating a long road ahead for domestic high-end development [3][4]. Summary by Sections Section 1: Domestic Substitution in Scientific Instruments - Tariff uncertainties and U.S. export controls are reshaping the landscape, making domestic substitution essential [3][7]. - The analysis instruments segment is a major branch of the scientific instruments industry, with high added value and a domestic market exceeding 30 billion yuan [3][17]. - R&D investment intensity is increasing, with 2024 funding reaching 3.61 trillion yuan, a growth of 8.3% year-on-year, surpassing the EU average [3][26]. Section 2: Barriers in Mass Spectrometry and Chromatography - The mass spectrometry market in China reached 16.704 billion yuan in 2023, growing by 19.53% year-on-year, but remains dominated by foreign brands [3][4]. - The chromatography market is projected to reach around 16 billion yuan in 2024, with significant potential for domestic substitution as import amounts decline [3][4]. Section 3: Innovation and R&D Focus - Companies like 聚光科技 (Juguang Technology) are turning losses into profits and diversifying their business models [4]. - 皖仪科技 (Wanyi Technology) is a leader in leak detection instruments, continuously investing in R&D [4]. - 莱伯泰科 (Leibotai Technology) is expanding from sample preparation to high-end analytical instruments, exploring new mass spectrometry technologies [4]. - 雪迪龙 (Xuedilong) is actively positioning itself in the scientific instruments market, benefiting from the expansion of the carbon market [4].